Please assess the completion status of the following clinical trial:

Trial Title: 68Ga-citrate PET/MR Imaging for Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery~* Age \>= 18 yrs.~* Karnofsky performance status of \>= 60~* Ability to understand a written informed consent document, and the willingness to sign it.~Cohort A:~- Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by immunohistochemistry of tissue biopsy~Cohort B:~- Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy~Exclusion Criteria:~* Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)~* Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Positive for PTEN deletion (Type: None): Confirmed by immunohistochemistry of tissue biopsy
- Negative for PTEN deletion (Type: None): Confirmed by immunohistochemistry of tissue biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).